TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) show a clinical benefit when used to treat patients with EGFR-mutated non-small-cell lung cancer (NSCLC), but this treatment unfortunately fails in patients with TKI-resistant tumors. We here provide evidence that TC-N19 (N19),...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, D-W, Chen, T-C, Huang, H-S, Lee, H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5108342/
https://www.ncbi.nlm.nih.gov/pubmed/27362807
http://dx.doi.org/10.1038/cddis.2016.192

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5108342/
https://www.ncbi.nlm.nih.gov/pubmed/27362807
http://dx.doi.org/10.1038/cddis.2016.192

Ejemplares similares